Premium
Menopausal hormone therapy: Currently no evidence for cardiac protection
Author(s) -
Wenger Nanette K.
Publication year - 2005
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20348
Subject(s) - medicine , estrogen , hormone therapy , hormone replacement therapy (female to male) , placebo , progestin , menopause , randomized controlled trial , clinical trial , hormone , disease , women's health initiative , heart disease , breast cancer , cancer , postmenopausal women , alternative medicine , pathology , testosterone (patch)
Coronary heart disease is the leading cause of death among women of older age. Interest emerged as to whether premenopausal endogenous estrogen conferred cardiac protection and whether menopausal hormone therapy might prove beneficial. The results of pivotal clinical trials including the randomized, placebo‐controlled hormone trial of the Women's Health Initiative (WHI) and the Heart and Estrogen/progestin Replacement Study (HERS) have led to new Guidelines from the American Heart Association (AHA) that state that hormone therapy should not be initiated or continued for the primary or secondary prevention of cardiovascular disease in menopausal women. Pediatr Blood Cancer 2005;44:625–629. © 2005 Wiley‐Liss, Inc.